These platforms, including pH‐responsive polymersomes, acid‐sensitive nanoparticles, polymeric prodrug systems, self‐degradable nanoparticles, and manganese‐silica nanoplatforms, have shown promising results in enhancing STING pathway activation, boosting antigen‐specific CD8+ T cell responses, and achieving robust tumor control across multiple preclinical models. Here, CD8A is linked to neoplasm.